SERP
Comments:
AM-6494 is a highly potent and orally bioavailable BACE1 inhibitor (IC50: 0.4 nM) with selectivity over BACE2 (IC50: 18.6 nM) and much higher selectivity over other aspartic proteases (Cathepsins D, E, Pepsin, Renin). However, users should note that no data is available on the activity of AM-6494 on other proteases and non-protease targets. Cross-species target activity has been confirmed in rat, mouse, dog and monkey assays with similar IC50 to the human enzyme and in vivo pharmacokinetic data is available in rat, dog and monkey (cynomolgus) indicating good utility in these model organisms. Other small molecule inhibitors with selectivity for BACE1 over BACE2 are available (PF-06751979 and BACE 1-In-4), however AM-6494 appears to be the most potent molecule against BACE1 with detailed in vivo pharmacokinetic profiles across rat, dog and monkey supporting its use in cell and in vivo models.
(last updated:
5 Mar 2024 )